Oramed Pharmaceuticals Inc. entered into an Option Agreement on July 22, 2025, granting Scilex the option to repurchase warrants for $27 million, with payment timelines and conditions outlined in the agreement. This follows their previous Secured Promissory Note deal worth $101.88 million and warrants to buy 13 million shares from Scilex.